Lonza Group AG (LONN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
At close: 05:30PM CEST
| Previous Close | 533.40 |
| Open | 530.80 |
| Bid | 534.40 x 0 |
| Ask | 549.00 x 0 |
| Day's Range | 528.40 - 546.20 |
| 52 Week Range | 308.60 - 589.40 |
| Volume | |
| Avg. Volume | 159,949 |
| Market Cap | 38.669B |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | 67.53 |
| EPS (TTM) | 7.94 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 4.00 (0.75%) |
| Ex-Dividend Date | May 13, 2024 |
| 1y Target Est | 715.25 |
ZacksAll You Need to Know About Lonza Group (LZAGY) Rating Upgrade to Strong Buy
Lonza Group (LZAGY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ReutersSwiss pharma firm Lonza's profit falls less than feared, shares rise
(Reuters) -Swiss contract drug manufacturer Lonza reported a smaller-than-expected decline in first-half profit on Thursday, as a strong performance in its core Biologics unit partly offset weak demand for capsules. Analysts at J.P. Morgan said the results may imply an upside potential to the annual core earnings margin guidance, and therefore expect shares to outperform. Lonza's Biologics unit produces monoclonal antibodies and drug conjugates, and comprises approximately 45% of its annual sales.
ZacksESLOY or LZAGY: Which Is the Better Value Stock Right Now?
ESLOY vs. LZAGY: Which Stock Is the Better Value Option?
© 2024 Yahoo. All rights reserved.